An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate

Trial Profile

An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Idebenone (Primary) ; Midazolam (Primary)
  • Indications Duchenne muscular dystrophy; Leber's hereditary optic atrophy; Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 23 Nov 2016 Status changed from not yet recruiting to completed.
    • 22 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top